Tag: NASDAQ:IMMP

. . Shares of Immumetp Ltd. . undefined, an Australian biotechnology listed on Nasdaq, rose 190% Thursday after the company posted positive results from a. . .

. . Small-cap immunotherapy company Immutep Ltd (ASX: IMM) is absolutely flying today. The Immutep share price is 57% higher. 14% at the time of writing. The company had some fantastic news to share this morning. . .

. . U.S. stock futures fell Thursday as U.S. lawmakers appeared to be far from reaching consensus on the terms of the next COVID-19 stimulus. Dow Jones Industrial Average Futures slipped 0. 1%, S&P futures fell 0. 2% and Nasdaq futures fell 0. 5%. On Wednesday, House Speaker Nancy Pelosi and Senate Minority

. . Immutep's Chinese partner (IMM), EOC Pharma, will start a phase II clinical trial in patients with metastatic breast cancer.

. . Global biotechnology company Immutep (ASX: IMM) has announced that its Chinese partner EOC Pharma will start a phase II clinical trial to evaluate the efficacy and safety of the lead drug eftilagimod alpha in the treatment of metastatic breast cancer.

. . Closing Bell is Stockhead's daily round-up of the ASX's biggest players - winners and losers alike. The data is collected after the market closes at 4 p.m. AEDT. Stocks highlighted in yellow rose after announcements. WINNERS Scroll or swipe to view the table. Click Headings to sort. Among the stocks with moving announcements, Biotech Immutep (ASX: IMM) held [...]

. . Immunotherapy company Immutep (ASX: IMM) announced what it describes as promising overall survival data from a breast cancer study with its eftilagimod. . .

Immutep Ltd (ASX: IMM) share price is up nearly 60% today following some encouraging results from the biopharmaceutical company's clinical trials